Home Newsfeeds Qualcomm Sees Q4 Sales $11B-$11.8B vs $11.87B Est.

Qualcomm Sees Q4 Sales $11B-$11.8B vs $11.87B Est.

-Reuters

byBill Haddad

July 27, 2022

1 minute read

-Reuters

EF Hutton Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $38

By Benzinga Newsdesk

December 16, 7:28 AM

EF Hutton analyst Elemer Piros initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Buy rating and announces Price Target of $38.

CMPS

FDA Raises Concerns Regarding Perrigo’s OTC Birth Control Pill, Casts Doubts Over Real-World Use

By Vandana Singh

May 8, 12:47 PM

The FDA's Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) will be meeting this week to review Perrigo Company plc's (NYSE: PRGO) Opill daily oral contraceptive for

PRGO

Kanzhun Q3 Adj Earnings Per ADS $0.12 Beats $0.08 Estimate, Sales $165.68M Beat $160.29M Estimate

By Benzinga Newsdesk

November 29, 7:27 AM

Kanzhun (NASDAQ:BZ) reported quarterly earnings of $0.12 per ADS which beat the analyst consensus estimate of $0.08 by 50 percent. This is a 7.69 percent decrease over earnings of $0.13 per share from the same period

Investigating Analog Devices’s Standing In Semiconductors & Semiconductor Equipment Industry Compared To Competitors

By Benzinga Insights

December 21, 12:00 PM

In today’s rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to…

ADI

Qualcomm Sees Q4 Sales $11B-$11.8B vs $11.87B Est.

Related Posts

EF Hutton Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $38

FDA Raises Concerns Regarding Perrigo’s OTC Birth Control Pill, Casts Doubts Over Real-World Use

Kanzhun Q3 Adj Earnings Per ADS $0.12 Beats $0.08 Estimate, Sales $165.68M Beat $160.29M Estimate

Investigating Analog Devices’s Standing In Semiconductors & Semiconductor Equipment Industry Compared To Competitors